Week in Review: OrbiMed Raises $800 Million for its Fourth Asia Fund

Deals and Financings   OrbiMed Advisors secured $3.5 billion in commitments for its latest capital raise, including $800 million for OrbiMed Asia Partners IV; SciClone Pharma, a Shanghai in-licensing company, staged a Hong Kong IPO that raised $279 million at a market cap of $1.6 billion; WuXi AppTec, a China-global CRO/CMO, paid $135 million to acquire Oxgene, a UK CDMO with a novel technology for developing cell and gene therapies; LianBio of Shanghai and and the US acquired China rights to a novel respiratory syncytial virus therapy from London 's ReViral in a $119 million deal; GenSciences, a commercial-stage Changchun drug company, raised over $124 million in its series A and B rounds to develop novel drugs; Connect Biopharma of Taicang filed for a NASDAQ IPO to raise $100 million for its T cell-driven inflammatory disease therapies; Biotheus, a Guangdong biotech, completed a $100 million Series D financing for immuno-oncology and metabolic disease drugs; Suzhou Medilink Therapeutics closed a $50 million Series A financing for next-gen antibody drug conjugate candidates; ABclonal Biotechnology of Wuhan acquired Yurogen Biosystems, a Boston CRO with a single cell drug discovery platform; Hangzhou Innoforce and dMed, a China-US clinical CRO, teamed up to partner innovative therapeutics being developed by third parties; Shanghai 's Junshi Bio out-licensed specific China marketing rights for its approved PD-1 to AstraZeneca; COVID-19 Pandemic   Suzhou 's Kintor Pharma reported the US FDA approved a Phase III trial of proxalutamide to treat male COVID-19 outpatients; Trials and Approvals   Apollomics, a Bay Area-Hangzhou biopharma, started a China Phase I trial of uproleselan in patients with relapsed or refractory acute myeloid leukemia; Innovent Bio of Suzhou started a US Phase I trial of its anti-CD47/PD-L1 bispecific antibody in patients with advanced malignancies. Stock Symbols: (HK: 6600) (HK: 1877; SHA: 688180) (NYSE: AZN) (HK: 9939) (HK: 01801) Share this with colleagues: // //